TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11260155

Group type: EXPERIMENTAL
Intervention: Salmeterol (SM) 50 microg, twice daily for 1 week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol (SM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 9731049

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 (8 weekly infusions) - Arm A
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg/m2 (1 infusion followed by 7 weekly infusions) - Arm B
Number of subjects: 54
Study: 7495064

Group type: EXPERIMENTAL
Intervention: Compression ultrasonography (CUS), Doppler ultrasound (DUS), and clinical score assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normal CUS, absence of venous reflux in both common femoral and popliteal vein, and low clinical score
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abnormal venous reflux in the isolated common femoral vein
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG) determination of venous refilling time
Number of subjects: 100
Study: 2658535

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 6
Study: 90602

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31957246

Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Manual hyperinflation
Number of subjects: 48
Study: 31828516

Group type: EXPERIMENTAL
Intervention: Wheeled Walker (WW) available
Number of subjects: 17

Group type: COMPARATOR
Intervention: No Wheeled Walker (WW) available
Number of subjects: 17
Study: 30935633

Group type: EXPERIMENTAL
Intervention: Self-reported frailty (≥ 1 symptom)
Number of subjects: 4996

Group type: EXPERIMENTAL
Intervention: Prefrail men (1 to 2 symptoms)
Number of subjects: 4996

Group type: EXPERIMENTAL
Intervention: Frail men (≥ 3 symptoms)
Number of subjects: 4996

Group type: EXPERIMENTAL
Intervention: Prefrail women (1 to 2 symptoms)
Number of subjects: 4996

Group type: EXPERIMENTAL
Intervention: Frail women (≥ 3 symptoms)
Number of subjects: 4996

Group type: EXPERIMENTAL
Intervention: Self-reported slow walk time and decreased physical activity
Number of subjects: 4996
Study: 28797049

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BICA) (0.3 g/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (4 g NaCl)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BICA)
Number of subjects: 18
Study: 25475947

Group type: EXPERIMENTAL
Intervention: Circular stapler technique
Number of subjects: 478

Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 478
Study: 25109453

Group type: EXPERIMENTAL
Intervention: Phonological-working memory training for four weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal classroom activities (Control)
Number of subjects: 19
Study: 23080477

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 19149890

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (80 mg/day of elemental iron) for one month
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 17897105

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study: 15128198

Group type: EXPERIMENTAL
Intervention: Wavelengths of 637, 656, 683 nm
Number of subjects: 26

Group type: COMPARATOR
Intervention: Wavelengths of 785 nm
Number of subjects: 26
Study: 12688516

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (two capsules per day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 4 weeks)
Number of subjects: 0
Study: 10428158

Group type: EXPERIMENTAL
Intervention: 24-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 21-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Number of subjects: 58
Study: 8672330

Group type: EXPERIMENTAL
Intervention: Preoxygenation with a good face mask seal (gravity alone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Preoxygenation with a face mask held adjacent to the face
Number of subjects: 16
Study: 2654865

Group type: EXPERIMENTAL
Intervention: Steroid treatment (higher initial doses: >= 125 mg of cortisone or >= 100 mg of hydrocortisone)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 1286
Study: 1240871

Group type: EXPERIMENTAL
Intervention: Armadillo lepromin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Human lepromin
Number of subjects: 112
Study: 31833102

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) in-home intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nurse (RN) telephone management
Number of subjects: 58
Study: 31618097

Group type: EXPERIMENTAL
Intervention: Visual speech
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Visual onset-offset cue
Number of subjects: 84

Group type: COMPARATOR
Intervention: Auditory-only condition
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Visual signal that only cued the onset and offset of the auditory syllable
Number of subjects: 84
Study: 28619043

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TENS) plus conventional clinical care
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional clinical care
Number of subjects: 208
Study: 25757070

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 65
Study: 24034663

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d, titrated to 10-20 mg/d)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 19705272

Group type: EXPERIMENTAL
Intervention: Erotic female images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clad female images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pleasantly arousing images (e.g., skydiving)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpleasantly arousing images (e.g., an aimed gun)
Number of subjects: 0
Study: 17574685

Group type: EXPERIMENTAL
Intervention: Number of previous episodes
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Severity of depression
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Social dysfunctioning
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Physical functioning
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Duration of the longest prior episode
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Coping potential
Number of subjects: 110
Study: 17040302

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 128

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 128
Study: 15211412

Group type: EXPERIMENTAL
Intervention: Subcutaneous ring block with levobupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous fentanyl (2 microg/kg) and paracetamol (30 mg/kg)
Number of subjects: 30
Study: 12082399

Group type: EXPERIMENTAL
Intervention: HPV DNA detection using polymerase chain reaction with E6/E7 and L1 primer sets
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Southern blot analysis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cloning and sequencing of HPV E6/E7 products
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Comparison of HPV sequences from cervical swab and breast cancer
Number of subjects: 17
Study: 9333933

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 2569

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study: 8002621

Group type: EXPERIMENTAL
Intervention: Thrice-weekly injection of Romurutide (3 times per week for 3 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Five times per week injection (5 times per week for 2 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thrice-weekly injection of Romurutide
Number of subjects: 22
Study: 2661880

Group type: EXPERIMENTAL
Intervention: Acetate Ringer dextrose (AR-D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactate Ringer dextrose (LR-D)
Number of subjects: 20
Study: 31864098

Group type: EXPERIMENTAL
Intervention: scIFN β‐1a tiw
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: scIFN β‐1a qw
Number of subjects: 517
Study: 31421060

Group type: EXPERIMENTAL
Intervention: Pythagorean Self‐Awareness Intervention (PSAI) + personalized Mediterranean low‐calorie diet
Number of subjects: 49

Group type: COMPARATOR
Intervention: Personalized Mediterranean low‐calorie diet
Number of subjects: 49
Study: 28112681

Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle (VCL)
Number of subjects: 14
Study: 26520928

Group type: EXPERIMENTAL
Intervention: Invitation plus tracing group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Invitation only group
Number of subjects: 200
Study: 23746949

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21975200

Group type: EXPERIMENTAL
Intervention: Interferon β‐1a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of 1-year MRI lesion activity and relapses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-year MRI lesion activity and relapses
Number of subjects: 0
Study: 19792848

Group type: EXPERIMENTAL
Intervention: PRP + ABBM
Number of subjects: 30

Group type: COMPARATOR
Intervention: ABBM alone
Number of subjects: 30
Study: 16822115

Group type: EXPERIMENTAL
Intervention: ST with CM for submitting negative urine toxicology screens
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: ST with CM for completing goal-related activities
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Longest duration of abstinence achieved during treatment
Number of subjects: 131
Study: 12580650

Group type: EXPERIMENTAL
Intervention: CHO-PRO beverage (355 ml; approximately 0.8 g carbohydrate (CHO).kg(-1) body wt and approximately 0.2 g protein.kg(-1) body wt)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO-PRO beverage
Number of subjects: 8
Study: 11030507

Group type: EXPERIMENTAL
Intervention: Foot function test (FBS, LS, TB, DP)
Number of subjects: 20
Study: 9049582

Group type: EXPERIMENTAL
Intervention: YM17E 150 mg twice daily (b.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: YM17E 300 mg twice daily (b.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7819790

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (Havrix, SKF) - 1 injection at day 0, 1 at D15, booster at 6 months
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine - 1 injection at day 0
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both hepatitis A and yellow fever vaccines
Number of subjects: 108
Study: 3308977

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bromocriptine + Desipramine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bromocriptine alone
Number of subjects: 36
Study: 30208343

Group type: EXPERIMENTAL
Intervention: 12-week stepped collaborative care intervention (cognitive behavioral therapy, CBT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Attention control arm of technology-delivered health education
Number of subjects: 150
Study: 27771036

Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 19

Group type: COMPARATOR
Intervention: Didactic education
Number of subjects: 19
Study: 26156512

Group type: EXPERIMENTAL
Intervention: Training with protein supplement (n = 18)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Training with placebo supplement (n = 13)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nonintervention control group (n = 10)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Postexercise protein-carbohydrate supplementation
Number of subjects: 61
Study: 22928719

Group type: EXPERIMENTAL
Intervention: Miltefosine (150 mg daily for 4 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 73
Study: 20216222

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400, 600 or 800 mg/day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 197
Study: 18820779

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ultrafiltration (Control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrafiltration and No ultrafiltration (Control)
Number of subjects: 40
Study: 17682259

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 921

Group type: COMPARATOR
Intervention: Social support
Number of subjects: 921

Group type: COMPARATOR
Intervention: Self-reported feelings of anger
Number of subjects: 921
Study: 14666762

Group type: EXPERIMENTAL
Intervention: Chinese Compound Changjitai (CJT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pinaverium bromide (PVB)
Number of subjects: 45
Study: 10713623

Group type: EXPERIMENTAL
Intervention: MEL-CY (cyclophosphamide 120 mg/kg + melphalan 200 mg/m2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MEL-TBI (total body irradiation 1125 cGy + melphalan 140 mg/m2)
Number of subjects: 43

Group type: COMPARATOR
Intervention: MEL200 (melphalan alone)
Number of subjects: 43
Study: 8693374

Group type: EXPERIMENTAL
Intervention: Current viral infection in children with pneumonia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overcrowding in homes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Occupancy of the room where the child slept
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Domestic smoke pollution
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 48

Group type: COMPARATOR
Intervention: Recurrence of respiratory symptoms
Number of subjects: 48

Group type: COMPARATOR
Intervention: Need to visit a health facility
Number of subjects: 48
Study: 1497051

Group type: EXPERIMENTAL
Intervention: Esterified estrogen 0.625 mg (Estratab)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Esterified estrogen 0.625 mg plus 1.25 mg methyltestosterone (Estratest H.S.)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen 0.625 mg (Premarin)
Number of subjects: 17
Study: 6689276

Group type: EXPERIMENTAL
Intervention: Oral administration of 500 mg of salicylamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal administration of 500 mg of salicylamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of 1500 mg of salicylamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal administration of 1500 mg of salicylamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of salicylamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal administration of salicylamide
Number of subjects: 0
Study: 30925415

Group type: EXPERIMENTAL
Intervention: Successful VBAC
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: None of the four intrapartum interventions (amniotomy, oxytocin, epidural, opioids)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Earlier performance of amniotomy (ARM)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Previous vaginal birth
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Longer labour duration
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Higher infant birthweight
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Amniotomy (ARM)
Number of subjects: 790
Study: 30373547

Group type: EXPERIMENTAL
Intervention: TRD patients
Number of subjects: 2467

Group type: COMPARATOR
Intervention: non-TRD patients
Number of subjects: 2467
Study: 26851494

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Paper-and-pencil measures
Number of subjects: 67
Study: 24707022

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 407
Study: 22584017

Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisone (6.25 mg/day) co-medication with methotrexate (MTX)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 220
Study: 20350619

Group type: EXPERIMENTAL
Intervention: TEAMcare intervention
Number of subjects: 0
Study: 17408866

Group type: EXPERIMENTAL
Intervention: Cue Only (lean towards beverage)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cue+Action (lift beverage towards them)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 188
Study: 16035056

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-mg QD
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 12010529

Group type: EXPERIMENTAL
Intervention: Nursing-led intermediate care in-patient units (NLIU)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control wards (16 wards referring patients to NLIU)
Number of subjects: 177
Study: 10534515

Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin sodium) 1 mg/kg body weight
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin sodium) 0.69 mg/kg (after dose reduction)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard unfractionated heparin
Number of subjects: 36
Study: 7781662

Group type: EXPERIMENTAL
Intervention: Candoxatril treatment on high sodium diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Candoxatril treatment on low sodium diet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (low sodium diet without candoxatril)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (high sodium diet without candoxatril)
Number of subjects: 8
Study: 2191189

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin (CIPII)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 5
Study: 7007260

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (blind control manner)
Number of subjects: 35
Study: 31662328

Group type: EXPERIMENTAL
Intervention: Standard care plus 72 hours of hypothermia (33.5°C±0.5°C, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care (n=25)
Number of subjects: 50
Study: 31045840

Group type: EXPERIMENTAL
Intervention: Oxycodone 2×ED95 (0.182 mg/kg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oxycodone ED95 (0.091 mg/kg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 μg/kg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oxycodone 0.269 mg/kg (recalculated ED95)
Number of subjects: 148
Study: 28671089

Group type: EXPERIMENTAL
Intervention: 2% liranaftate ointment
Number of subjects: 1100

Group type: COMPARATOR
Intervention: 1% bifonazole cream
Number of subjects: 1100
Study: 25884300

Group type: EXPERIMENTAL
Intervention: Community-based health worker led case management approach
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care (waitlist control group)
Number of subjects: 213
Study: 23478248

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 600 mg plus three-drug regimen (pantoprazole 40 mg BD, ciprofloxacin 500 mg BD, bismuth subcitrate 120 mg two tablets BD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus three-drug regimen (pantoprazole 40 mg BD, ciprofloxacin 500 mg BD, bismuth subcitrate 120 mg two tablets BD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 60
Study: 20546968

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin (GC)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gemcitabine, Carboplatin, and Docetaxel (GCD)
Number of subjects: 123
Study: 19573904

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Ketamine (2 mg/kg)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 655

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 655
Study: 17449250

Group type: EXPERIMENTAL
Intervention: erbB2+ cluster
Number of subjects: 50

Group type: COMPARATOR
Intervention: normal-like cluster
Number of subjects: 50

Group type: COMPARATOR
Intervention: basal-like cluster
Number of subjects: 50

Group type: COMPARATOR
Intervention: luminal cluster
Number of subjects: 50
Study: 15386160

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3 plus 1 g calcium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11318022

Group type: EXPERIMENTAL
Intervention: Foam ear plugs under headset
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hi-fi plugs under headset
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Custom made ear plugs under headset
Number of subjects: 9

Group type: COMPARATOR
Intervention: Headset only
Number of subjects: 9
Study: 9044475

Group type: EXPERIMENTAL
Intervention: rt‐PA plus heparin (H) (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin (H) alone (n = 10)
Number of subjects: 20
Study: 8196289

Group type: EXPERIMENTAL
Intervention: 100 mg losartan
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3630891

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment (3.6 mg/kg lysine salt of acetylsalicylic acid, corresponding to 2 mg/kg aspirin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No aspirin pretreatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 14